PROCEPT BioRobotics reported a 20% revenue increase to $83.1 million in Q1 2026, driven by strong U.S. system sales and improved pricing. The company completed about 12,200 U.S. procedures, a 30% rise from last year, and expanded its U.S. installed base by 40%. Operating expenses rose due to investments in commercial expansion and clinical trials, resulting in a net loss of $31.6 million. PROCEPT also received FDA clearance for its second-generation AI software enhancing its HYDROS robotic system, supporting future growth. The company expects full-year 2026 revenue between $390 million and $410 million, with continued procedure growth and stable gross margins.
Sodexo has secured a major global contract to provide catering services across more than 130 Meta sites in over 30 countries. This large-scale partnership includes diverse locations such as headquarters, campuses, data centers, and conference centers...
Gabriel Holding A/S has agreed to sell its European FurnMaster furniture manufacturing operations, including subsidiaries in Poland and Lithuania, to Leggett & Platt for an initial price of approximately EUR 9 million, with a possible additional paym...
DMG Blockchain Solutions announced two strategic investments: one in MeetAmi Innovations, a Canadian fintech offering digital asset wealth management platforms, and another in Atomic47 Labs, an AI company focused on secure, sovereign AI infrastructur...
Gnosis (GNO) surged 13% in 24 hours, closing in on overtaking BONK by market capitalization to reach the 100th largest token spot. GNO's market cap stands at $303.88 million versus BONK's $330.07 million, requiring a price rise to about $125.48 for t...
Broadridge's Tokenization Pulse Survey shows 84% of firms view tokenization as strategically important, with 68% expecting it to reshape markets within 3-5 years. Most firms plan to integrate tokenization into existing infrastructure rather than buil...
